3.85%C 7.22 11.94%GE 17.61 13.61%
The Global Business News Leader | Tuesday, 2 Dec 2008
- EQUITY MARKETS
- BONDS AND RATES
- FOREX
- COMMODITIES
- LANGUAGES
- FUNDS
- RETIREMENT
- TAXES
- INSURANCE
- INVESTING
- LANGUAGES
- MOVIE
- MUSIC
- TV
- CELEBRITIES
- LANGUAGES
OSIRIS THERAPEUTICS INC.
OSIR (NASDAQ)
$ 20.76 
Change: +1.06 +5.11% | Volume: 485,170
Change: +1.06 +5.11% | Volume: 485,170
Sponsored by 
OSIRIS THERAPTC - Fundamental Profile
Company Information
| Ticker Symbol: | OSIR |
|---|---|
| Exchange: | NASD |
| Contact Info: | 7015 Albert Einstein Drive Columbia MD 21046-1707 443-545-1800 |
| CEO/President: | |
| Industry: | Medical - Biomedical / Standard Industry Code: 2836 |
| Description: | OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn\'s disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. |
Share Information
| Shares Outstanding: | 31,810 (000) | Market Value: | 605,310 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 12.08% | Number of Inst.Shareholders: | 49.70% |
| Last Quarter Sales: | 1.00 ($Mil.) | Last Quarter Net Income: | 5.25 ($Mil.) |
| Last Quarter EPS: | -0.63 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -1.53 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
Top Competitors
| AMGEN INC. |  |
+7.80 | 54.77 |
| GILEAD SCIENCES |  |
-16.80 | 42.46 |
| CELGENE CORPORA | |
-26.90 | 47.82 |
| GENENTECH INC | |
-4.90 | 71.80 |
| GENZYME CORPORA | |
-28.20 | 57.70 |
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives